Literature DB >> 12849012

Role of profibrogenic cytokines secreted by T cells in fibrotic processes in scleroderma.

Tracy L McGaha1, Constantin A Bona.   

Abstract

IL-4 is potentially a major profibrogenic cytokine upregulating the expression of collagen genes. In vivo studies have shown that the disruption of STAT6, IL-4R, IL-4 or transforming growth factor-beta (TGF-beta) genes in TSK mice, which develop scleroderma-like syndrome, prevented the occurrence of skin sclerosis and of autoantibodies. Additionally, it is known that the homozygosity of TSK mutation is lethal and the embryos die by day 7-8 of pregnancy. The disruption of IL-4 gene rescued from death TSK/TSK mice suggesting a role for IL-4 in embryonic development. Since TGF-beta should compensate the lack of IL-4 on regulation of collagen gene expression, we have studied the effect of IL-4 on the expression of TGF-beta gene. Our results showed IL-4 dependence of the transcription of TGF-beta gene and that in both TSK/+ and TSK/TSK IL-4-/- mice the expression of TGF-beta gene is impaired.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12849012     DOI: 10.1016/s1568-9972(02)00027-7

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  13 in total

1.  Association between 'interleukin' 10 gene (IL10) polymorphisms and systemic sclerosis with interstitial lung involvement.

Authors:  O Ates; B Müsellim; G Ongen; A Topal-Sarikaya
Journal:  Rheumatol Int       Date:  2008-05-21       Impact factor: 2.631

2.  B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.

Authors:  Minoru Hasegawa; Yasuhito Hamaguchi; Koichi Yanaba; Jean-David Bouaziz; Junji Uchida; Manabu Fujimoto; Takashi Matsushita; Yukiyo Matsushita; Mayuka Horikawa; Kazuhiro Komura; Kazuhiko Takehara; Shinichi Sato; Thomas F Tedder
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

3.  Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets.

Authors:  Matthew B Greenblatt; Jennifer L Sargent; Giuseppina Farina; Kelly Tsang; Robert Lafyatis; Laurie H Glimcher; Michael L Whitfield; Antonios O Aliprantis
Journal:  Am J Pathol       Date:  2012-01-11       Impact factor: 4.307

Review 4.  Pharmacotherapy of systemic sclerosis.

Authors:  Arnold E Postlethwaite; L Jeff Harris; Syed H Raza; Swapna Kodura; Titilola Akhigbe
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

5.  B cells: no longer bystanders in liver fibrosis.

Authors:  Rashpal K Bhogal; Constantin A Bona
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

Review 6.  Liver fibrosis: mechanisms of immune-mediated liver injury.

Authors:  Ruonan Xu; Zheng Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2011-12-12       Impact factor: 11.530

7.  Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13.

Authors:  Antonios O Aliprantis; Jingsong Wang; John W Fathman; Raphael Lemaire; David M Dorfman; Robert Lafyatis; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-16       Impact factor: 11.205

Review 8.  Molecular aspects of regulation of collagen gene expression in fibrosis.

Authors:  Rashpal K Bhogal; Cristina M Stoica; Tracy L McGaha; Constantin A Bona
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

Review 9.  The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets.

Authors:  Julie K Nguyen; Evan Austin; Alisen Huang; Andrew Mamalis; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2019-09-06       Impact factor: 3.017

10.  Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.

Authors:  Pravitt Gourh; Frank C Arnett; Shervin Assassi; Filemon K Tan; Mei Huang; Laura Diekman; Maureen D Mayes; John D Reveille; Sandeep K Agarwal
Journal:  Arthritis Res Ther       Date:  2009-10-02       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.